Ken Jiang - Department of Medicine, University of Chicago

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 14 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Final Analysis of a Phase II Trial of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Without Transplant

Benjamin A. Derman,Jennifer Cooperrider,Jacalyn Rosenblatt,David E. Avigan,Murtuza Rampurwala,David Barnidge,Ajay Major,Theodore Karrison,Ken Jiang,Aubrianna Ramsland,Tadeusz Kubicki,Andrzej J. Jakubowiak

Blood Cancer Journal（2024）

引用0浏览0WOSNATURE引用

Competing Risk Nomogram and Risk Classification System for Evaluating Overall and Cancer-Specific Survival in Neuroendocrine Carcinoma of the Cervix: a Population-Based Retrospective Study

J. Liu, Y. Lyu, Y. He,J. Ge,W. Zou, S. Liu, H. Yang,J. Li,K. Jiang

JOURNAL OF ENDOCRINOLOGICAL INVESTIGATIONno. 6 (2024): 1545-1557

引用0浏览0WOS引用

Discontinuation of Maintenance Therapy in Multiple Myeloma Guided by Multimodal Measurable Residual Disease Negativity (MRD2STOP)

Benjamin Avi Derman,Jennifer H. Cooperrider,Tadeusz Kubicki,Ajay Major,Ken Jiang,Aubrianna Ramsland, Karson Buckley, Samrawit Melka,Amanda McIver,Theodore Karrison,Andrzej J. Jakubowiak

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

引用0浏览0WOSNATURE引用

A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma

Benjamin A. Derman,Ajai Chari,Jeffrey Zonder,Ajay Major,Andrew T. Stefka,Ken Jiang,Theodore Karrison,Jagoda Jasielec,Andrzej Jakubowiak

Eur J Haematol（2023）

引用2浏览0WOS引用

Early Peripheral Blood Minimal Residual Disease Status By NGS in Patients with Newly Diagnosed Multiple Myeloma (MM) on a Phase 2 Trial Receiving Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd)

Ben A Derman,Tadeusz Kubicki,Heidi Simmons,Aimaz Afrough,Jeffrey A. Zonder,David L. Grinblatt,Larry D. Anderson,Andrew Kin,Sunil Narula,Shayan Rayani,Sandeep Gurbuxani,Theodore Karrison,Ken Jiang,Ajay Major,Jennifer H Cooperrider,Allison P. Jacob,Andrzej J Jakubowiak

Blood (2023): 1982

引用0浏览0引用

Early Peripheral Blood Minimal Residual Disease Status by NGS in Patients with Newly Diagnosed Multiple Myeloma (MM) on a Phase 2 Trial Receiving Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-Krd)

Ben A Derman,Tadeusz Kubicki,Heidi Simmons,Aimaz Afrough,Jeffrey A. Zonder,David L. Grinblatt,Larry D. Anderson,Andrew Kin,Sunil Narula,Shayan Rayani,Sandeep Gurbuxani, Theodore Karrison,Ken Jiang,Ajay Major,Jennifer H. Cooperrider,Allison P. Jacob,Andrzej Jakubowiak

Bloodno. Supplement 1 (2023): 1982-1982

引用0浏览0引用

Final Analysis of a Phase 2 Trial of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma (NDMM) Without Autologous Stem Cell Transplantation (ASCT)

Benjamin A Derman,Jennifer H Cooperrider,Jacalyn Rosenblatt,David Avigan,Murtuza M. Rampurwala,Ajay Major,Theodore Karrison,Ken Jiang,Tadeusz Kubicki,Andrzej J Jakubowiak

Bloodno. Supplement 1 (2023): 4747-4747

引用0浏览0引用

Longitudinal Assessment of Minimal Residual Disease (MRD) in the ATLAS Randomized Phase 3 Trial of Post-Transplant Treatment with Carfilzomib, Lenalidomide, and Dexamethasone (krd) Versus Lenalidomide (R) Alone in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Blood（2023）

引用0浏览0引用

Prospective Trial Using Multimodal Measurable Residual Disease Negativity to Guide Discontinuation of Maintenance Therapy in Multiple Myeloma (MRD2STOP)

Ben A. Derman,Ajay Major,Sarah Major,Brittany D. Wolfe,Martha Gorski,Jennifer H. Cooperrider,Evangelia Andreatos,Ken Jiang, Karson Buckley,Amanda McIver,Andrew Stefka,Andrzej Jakubowiak

Blood（2022）

引用1浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn